Featured News

2

Understanding resistance to targeted therapies in head and neck,...

July 11, 2025

MSN highlighted University of Cincinnati Cancer Center and Cincinnati Veterans Affairs Medical Center research published in the journal Oncotarget that reviewed current research on why Epidermal Growth Factor Receptor-targeted therapies often fail in breast and head and neck cancers.

3

What parvovirus is and why it's on the rise

July 10, 2025

An infectious virus common in children is on the rise in the Tristate. The Cincinnati Health Department is warning of a rise in parvovirus in Hamilton County. The illness can present itself as a rash on the cheeks and is often called “slapped cheek” disease but can present more serious concerns in pregnant women. Kara Markham, MD, professor of obstetrics and gynecology at the University of Cincinnati College of Medicine recently appeared on Cincinnati Edition on WVXU to discuss how parvovirus is transmitted, the risk of serious cases and how to prevent it.

Debug Query for this

Latest News

2

Understanding resistance to targeted therapies in head and neck,...

July 11, 2025

MSN highlighted University of Cincinnati Cancer Center and Cincinnati Veterans Affairs Medical Center research published in the journal Oncotarget that reviewed current research on why Epidermal Growth Factor Receptor-targeted therapies often fail in breast and head and neck cancers.

3

What parvovirus is and why it's on the rise

July 10, 2025

An infectious virus common in children is on the rise in the Tristate. The Cincinnati Health Department is warning of a rise in parvovirus in Hamilton County. The illness can present itself as a rash on the cheeks and is often called “slapped cheek” disease but can present more serious concerns in pregnant women. Kara Markham, MD, professor of obstetrics and gynecology at the University of Cincinnati College of Medicine recently appeared on Cincinnati Edition on WVXU to discuss how parvovirus is transmitted, the risk of serious cases and how to prevent it.

4

Inflammation, not symptoms, found to disrupt sleep in IBD...

July 9, 2025

Impaired sleep architecture in inflammatory bowel disease (IBD) is primarily driven by inflammatory activity rather than symptomatic flares as previously thought, according to a study published in Clinical Gastroenterology and Hepatology. Sleep architecture is the structural organization of a normal sleep cycle, encompassing the progression and distribution of different stages of sleep throughout a typical night’s rest.

5

Study traces evolutionary origins of important enzyme complex

July 8, 2025

New University of Cincinnati Cancer Center research published in the journal Nature Communications traced the evolutionary origins of the PRPS enzyme complex and learned more about how this complex functions and influences cellular biochemistry.

6

UC study explores fertility treatment risks for kidney...

July 7, 2025

Women with kidney transplants who use assisted reproductive technology (ART) to conceive might face higher risks of complications during pregnancy, according to new research from the University of Cincinnati College of Medicine.

8

UC students plan free pop-up medical clinic

July 1, 2025

The University of Cincinnati's chapter of Remote Area Medical, in collaboration with Anthem Blue Cross and Blue Shield, will host a free clinic at St. Xavier High School on July 19-20.

12

Multi-institutional team awarded NCI grant to open novel AML...

June 23, 2025

The University of Cincinnati Cancer Center, The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and Jabez Biosciences are partnering to open a new phase 1 clinical trial studying JBZ-001, a potential new treatment for acute myeloid leukemia, funded by a National Cancer Institute grant.

13

Novel drug achieves high objective response rate in heavily...

June 18, 2025

Cancer Network News highlighted research led by the University of Cincinnati Cancer Center's Zulfa Omer that found a novel drug was generally well tolerated and demonstrated early efficacy in patients with relapsed/refractory chronic lymphocytic leukemia.

Load More
Debug Query for this